Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Improving Lives, Offering Hope Nyrada is Developing New Therapies for Cardiovascular and Neurological Disorders

Learn more

Company Overview

Nyrada is a pre-clinical stage, drug development company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases.

The Company’s vision is to become a high growth bio-pharmaceutical company specialising in drug discovery and early stage drug development, based mainly around the benzopyran molecular scaffold and focusing on areas of substantial unmet clinical need, where few if any, effective or well-tolerated therapies exist.

The Company has four current drug development programs:

  • Cardiovascular: a PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs
  • Neuroprotection: a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury
  • Inflammation/pain: a drug to treat pain associated with peripheral nerve damage, and
  • Inflammation/autoimmunity: a drug to treat autoimmune diseases such as psoriasis.

Download Prospectus

Board of Directors

Scientific Advisory Board

Management Team

Share Price

Market Cap:
Price Delay ~20min

Features

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis rutrum sapien non ornare sagittis. Fusce quis dignissim felis. Pellentesque iaculis nisl et est ultricies, id mollis lorem volutpat.

Read More
 

Latest News

More News

Why Invest

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis rutrum sapien non ornare sagittis. Fusce quis dignissim felis. Pellentesque iaculis nisl et est ultricies, id mollis lorem volutpat.

Pellentesque iaculis nisl et est ultricies, id mollis lorem volutpat.

Read More
 

Disclaimer

Important Notice

The Prospectus on this website (Offer Document) relates to the offer of Chess Depositary Interests (CDIs) by Nyrada Inc. ARBN 625 401 818 (Nyrada) and has been prepared to comply with the requirements of the securities laws of Australia. An electronic version of the Offer Document is accessible from this website. Before you attempt to access the electronic version of the Offer Document on this website, you must read this notice in its entirety and indicate your agreement at the bottom of this notice to the terms of access contained on this webpage. If you agree to the terms and conditions contained on this page, you will be given access to the electronic version of the Offer Document.

If you access the electronic version of the Offer Document, you should ensure that you download and consider the Offer Document in full.

Jurisdiction

Access to the electronic version of the Offer Document is for use only by:

  • residents of Australia from within Australia;

  • "professional investors" (as defined in the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong) from within Hong Kong;

  • "institutional investors" or "relevant persons" (as defined under the Securities and Futures Act, Chapter 289 of Singapore) from within Singapore; or

  • "qualified investors" (as defined under section 86(7) of the Financial Services and Markets Act 2000) from within the United Kingdom.

It must not be released or distributed in the United States or in any jurisdiction outside of Australia where distribution may be restricted by law.

The Offer Document on this website does not constitute an offer of CDIs in the United States or to any person to whom it would not be lawful outside Australia. The CDIs referred to herein have not been, and will not be, registered under the U.S. Securities Act or under the securities laws of any state or other jurisdiction of the United States. Any CDIs described in, or sold pursuant to, the Offer Document may not be offered or sold in the United States absent registration under the Securities Act or pursuant to an applicable exemption from registration, or to any person to whom it would not be lawful outside Australia.

The CDIs being offered pursuant to the Offer Document are being made available to investors in reliance on the exemption from registration contained in Regulation S of the U.S. Securities Act for offers which are made outside of the U.S. As a result of relying on the Regulation S exemption, the CDIs being offered pursuant to the Offer Document are subject to the restrictions under Regulation S.

Investors must seek advice

Nothing contained on this website or in the Offer Document constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Offer Document does not take into account your individual investment objectives, financial or taxation situation or particular needs. In making an investment decision, you must rely on your own examination of Nyrada, the CDIs and the terms of the offer, including the merits and risks involved. You should consult with your accountant, financial adviser, stockbroker, lawyer, tax adviser or other independent and qualified professional adviser if you have any questions in relation to the offer.

Application Form

The paper form of the electronic version of the Offer Document (including its attached Application Form) accessible through this website has been lodged with the Australian Securities and Investments Commission (ASIC).

Nyrada will apply within 7 days of date of the Offer Document to the Australian Securities Exchange (ASX) for admission to the official list of the ASX and for quotation of the CDIs of Nyrada. Neither ASIC nor ASX takes any responsibility for the contents of the Offer Document or the investment to which it relates.

No offer of CDIs is made on the basis of the electronic version of the Offer Document accessible through this website. An application for CDIs can be made in accordance with the details set out in the Offer Document and the Application Form.

Acceptance of Conditions

By accessing the Offer Document, you represent, warrant and agree that:

  1. you have read, understood and agree to the terms contained in this notice;

  2. you are:

    1. a resident of Australia accessing this website from Australia;

    2. a "professional investor" (as defined above) accessing this website from Hong Kong;

    3. a "institutional investor" or "relevant person" (as defined above) accessing this website from Singapore; or

    4. a "qualified investor" (as defined above) accessing this website from the United Kingdom;

  3. you are not a U.S. Person or a person in the United States and you are not acting for the account or benefit of a U.S. Person or a person in the United States; and

  4. you will not release or distribute the Offer Document in the United States or to any U.S. Person or person in the United States or in any other place in which, or to any other person to whom, it is unlawful to do so.